A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India

Kidney Transplantation Clinical Trial

Official title:

An Open Label, Multi-centre, Prospective Study to Demonstrate Safety and Efficacy of Once Daily Advagraf in Patients Undergoing Kidney or Liver Transplantation in India

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02432053
• Other study ID #: F506-CL-0894
• Secondary ID: AS/111/10
• Status: Completed
• Phase: Phase 4
• First received: April 28, 2015
• Last updated: April 28, 2015
• Start date: March 2012
• Est. completion date: May 2013

Study information

• Verified date: April 2015
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: India: Central Drugs Standard Control Organization
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to demonstrate safety and efficacy of once-daily Advagraf in adult population undergoing kidney or liver transplantation in India.

Description:

This is a phase IV, multi-centre, open label prospective study of once daily Advagraf in 200 patients undergoing kidney or liver transplantation in India. Adult patients undergoing kidney or liver transplantation and meeting all other eligibility criteria will be enrolled in the study. Enrolled patients will be administered once daily dose of Advagraf for 12 weeks. During these 12 weeks a total of 9 regular visits will be undertaken.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: May 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria (common to kidney and liver transplant patients):

• Male or female patients between 18 to 65 years of age, undergoing liver or kidney transplantation

• Female patients of child bearing potential must have a negative serum pregnancy test prior to enrolment and must agree to practice effective birth control during the study. Tacrolimus may reduce the clearance of steroid based contraceptives leading to increased hormone exposure; particular care should be exercised when deciding upon contraceptive measures.

• Patients should be capable of understanding the purpose and risks of the study, and should provide written informed consent to participate in the study.

Inclusion Criteria (specifically for kidney transplant patients):

• Patients with end stage kidney disease and who are a suitable candidate for primary kidney transplantation.

• Patients scheduled to receive a kidney transplant from a cadaveric or living donor between 5 and 65 years of age with compatible ABO blood type.

Inclusion Criteria (specifically for liver transplant patients):

• Patients with end stage liver disease and who are a suitable candidate for primary liver transplantation.

• Patients scheduled to receive a liver transplant from a cadaveric or living donor between 5 and 65 years of age with compatible ABO blood type.

Exclusion Criteria (common to kidney and liver transplant patients):

• Previously received or are scheduled to receive an organ transplant other than kidney or liver

• Undergoing re-transplant from either a cadaveric or living donor

• Contraindication to the use of tacrolimus or corticosteroids.

• Malignancy or history of malignancy within the last 5 years, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.

• Systemic infection requiring treatment.

• Transplantation of kidney or liver from non-heart beating donor.

• Severe diarrhea, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus.

• Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the patient.

• Simultaneously participating in another investigational drug study or has participated in such study within 28 days prior to entry in this study.

• Receiving any non-registered medication or has received any non-registered medication within 28 days prior to entry in this study.

• Pregnant women or breast-feeding mother.

• Patients or respective donors known to be positive for human immunodeficiency virus (HIV).

• Unlikely to comply with the visits scheduled in the protocol.

Exclusion criteria (Specifically for kidney transplant patients)

• Cold ischemia time of the donor kidney > 30 hours.

• High immunological risk, defined as a positive cross match or PRA grade 50% in the previous 6 months.

• Liver cirrhosis.

• Significant liver disease, defined as having either elevated serum glutamic pyruvic transaminase / alanine aminotransferase(SGPT / ALT) (at least 2.5 times the upper value of the normal range at the investigational site) or elevated serum glutamic oxaloacetic transaminase/ aspartate transaminase (SGOT/AST) (at least 2.5 times the upper value of the normal range at the investigational site) or elevated total bilirubin levels (at least 2.5 times the upper value of the normal range at the investigational site) or all of them during the 28 days prior to entry into the study.

• Patients or respective donors known to be positive for hepatitis B virus (HBV) or hepatitis C virus (HCV).

Exclusion Criteria (specifically for liver transplant patients):

• Transplanted for hepatocellular carcinoma with a single nodule greater than 5.0 cm in diameter or more than 3 nodules or metastases or vascular tumoral invasion.

• Serum creatinine 2mg/dL.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Kidney Transplantation
• Liver Transplantation

Intervention

Drug:
• Advagraf

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Renal function (evaluated by level of Serum Creatinine)		from Day 0 to Week 12	Yes
Primary	Lipid profile		0, 4, and 12-week	Yes
Primary	Incidence of New-Onset Diabetes Mellitus After Transplant (NODAT)	NODAT is defined as a composite endpoint consisting of first occurrence of one of 4 parameters: (1) Two fasting plasma glucose (FPG) levels > 126 mg/dL which are > 30 days apart. (2) Oral hypoglycemic agent use for > 30 consecutive days. (3) Insulin therapy for > 30 consecutive days and (4) HbA1c > 6.5%	from Day 0 to Week 12	Yes
Primary	Incidence of infection		from Day 0 to Week 12	Yes
Primary	For kidney transplant patients: Event rate of patients with biopsy-confirmed acute rejections (BCAR) = Grade I according to ?The Banff 2007 working classification of renal allograft pathology within the first 12 weeks following kidney transplantation	The biopsy shall be performed prior to the initiation of any anti-rejection therapy and as soon as possible after the onset of clinical / laboratory signs indicative of possible rejection	from Day 0 to Week 12	No
Primary	For liver transplant patients: Event rate of patients with biopsy-confirmed acute rejections (BCAR) with Rejection Activity Index of = 4, within the first 12 weeks following liver transplantation	The biopsy shall be performed prior to the initiation of any anti-rejection therapy and as soon as possible after the onset of clinical / laboratory signs indicative of possible rejection. Biopsy-confirmed acute rejections (BCAR) with Rejection Activity Index was defined according to The 1997 Banff schema for grading liver allograft rejection	from Day 0 to Week 12	No
Secondary	Time to first biopsy confirmed acute rejection episode		from Day 0 to Week 12	No
Secondary	Overall frequency of acute rejection episodes		from Day 0 to Week 12	No
Secondary	Severity of biopsy confirmed acute rejections		from Day 0 to Week 12	No
Secondary	Incidence of corticosteroid resistant rejection		from Day 0 to Week 12	No
Secondary	Incidence of corticosteroid sensitive rejection		from Day 0 to Week 12	No
Secondary	Incidence of use of anti-lymphocyte antibodies		from Day 0 to Week 12	No
Secondary	Graft loss		Week 12	No
Secondary	Death		Week 12	No